Organization | Institut de Cancérologie de la Loire (ICLN)

Institut de Cancérologie de la Loire (ICLN) Report issue

Academic/Hospital Phase 2 Phase 3

Founded: Saint-Priest-en-Jarez France (2003)

Organization Overview

First Clinical Trial

2009

NCT00985855

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Institut de Cancérologie de la Loire

Active Ingredients

Drugs in Phase 3 Trials (3)

bee venom (1 trial)

belladonna (1 trial)

radium-223 (xofigo) (1 trial)

Drugs in Phase 2 Trials (11)

capsaicin (qutenza) (1 trial)

cetuximab (erbitux) (1 trial)

cisplatin (platinol) (1 trial)

etoposide (vepesid) (1 trial)

fibrinogen (human) (RiaSTAP) (1 trial)

lenalidomide (revlimid) (1 trial)

lidocaine (xylocaine) (1 trial)

ropivacaine (naropin) (1 trial)

tranexamic acid (cyklokapron) (1 trial)

vinorelbine (navelbine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Feeding and Eating Disorders (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Neoplasms (Phase 2)

Neuralgia (Phase 2)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Radiodermatitis (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 7
# of Trial APIs: 14